Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Climb Bio Inc (NASDAQ: CLYM) was $4.0 for the day, down -0.74% from the previous closing price of $4.03. In other words, the price has decreased by -$0.74 from its previous closing price. On the day, 0.64 million shares were traded. CLYM stock price reached its highest trading level at $4.06 during the session, while it also had its lowest trading level at $3.88.
Ratios:
Our analysis of CLYM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 18.38 and its Current Ratio is at 18.38. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 13, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $9.
On August 15, 2025, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $9.Robert W. Baird initiated its Outperform rating on August 15, 2025, with a $9 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 11 ’25 when RA CAPITAL MANAGEMENT, L.P. bought 213,099 shares for $2.18 per share. The transaction valued at 464,556 led to the insider holds 3,294,856 shares of the business.
RA CAPITAL MANAGEMENT, L.P. bought 101,462 shares of CLYM for $290,181 on Dec 12 ’25. The Director now owns 3,396,318 shares after completing the transaction at $2.86 per share. On Jun 30 ’25, another insider, Brennan Aoife, who serves as the President and CEO of the company, sold 20,618 shares for $1.22 each. As a result, the insider received 25,154 and left with 48,132 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLYM now has a Market Capitalization of 272737728 and an Enterprise Value of 186416736.
Stock Price History:
The Beta on a monthly basis for CLYM is -0.08, which has changed by 0.7777778 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, CLYM has reached a high of $5.05, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 57.83%, while the 200-Day Moving Average is calculated to be 120.63%.
Shares Statistics:
CLYM traded an average of 1.30M shares per day over the past three months and 1232390 shares per day over the past ten days. A total of 68.18M shares are outstanding, with a floating share count of 62.43M. Insiders hold about 8.44% of the company’s shares, while institutions hold 45.75% stake in the company. Shares short for CLYM as of 1765756800 were 2219442 with a Short Ratio of 1.70, compared to 1763078400 on 1540104. Therefore, it implies a Short% of Shares Outstanding of 2219442 and a Short% of Float of 6.0500003.
Earnings Estimates
A comprehensive evaluation of Climb Bio Inc (CLYM) is underway, with the input of 2 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.18 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.81 and -$0.81 for the fiscal current year, implying an average EPS of -$0.81. EPS for the following year is -$0.81, with 2.0 analysts recommending between -$0.72 and -$0.9.
